Cover Image
市場調查報告書

MediPoint: 切片設備 - 歐盟市場分析及未來預測

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

出版商 GlobalData 商品編碼 297032
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint: 切片設備 - 歐盟市場分析及未來預測 MediPoint: Biopsy Devices - EU Analysis and Market Forecasts
出版日期: 2014年02月28日 內容資訊: 英文 131 Pages
簡介

癌症是體內異常細胞無法控制地增加,影響各種內臟器官和組織。對於疑似得到某種癌症患者,透過生物檢驗對患者進行確定性癌症診斷。受到這些生物檢驗重要性的影響,醫療設備廠商最大化標本的品質及數量,開發同時能減少患者負擔的切片設備,確立更微創的切片檢查技術作為全球各地新標準。

本報告提供EU之切片設備市場相關調查分析、產業概要、競爭評估、未滿足需求、開發中產品相關驗證、企業簡介、市場預測與預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 切片檢查的種類
  • 切片檢查方法趨勢
  • 對癌症診察計劃的市場進入
  • 法規的問題/回收
  • M&A/主要的夥伴關係
  • 癌症診察、治療的經濟影響
  • 切片設備的其他適應症

第4章 未滿足需求

  • 概要
  • 前列腺癌的有效率診察
  • 乳癌的有效率診察
  • 甲狀腺癌的有效率診察的指南
  • 可提供組織學性分析的診察

第5章 市場機會分析

  • 歐洲各國的真空輔助切片檢查(VAB)設備市場
  • 解決方案套組
  • 中國的VAB設備採用的增加
  • 歐洲的前列腺癌檢驗市場

第6章 推動市場要素與阻礙

  • 推動市場要素
  • 市場障礙

第7章 競爭評估

  • 概要
  • 系統為基礎分類

第8章 開發平台評估

  • 概要

第9章 臨床試驗分析

第10章 現在/未來的主要企業

  • 企業策略趨勢
  • 企業簡介

第11章 市場預測

  • 企業的市場佔有率
  • 各市場區隔
  • 各地區
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國

第12章 附錄

目錄
Product Code: GDME1085CFR

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.

Scope

  • An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized EU biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019.
  • Investigation of current and future market competition for biopsy devices
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the biopsy devices sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL).

Reasons to buy

  • Understand the trends shaping and driving EU biopsy devices Market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in EU biopsy devices market through 2019.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in EU biopsy devices market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Overview
  • 2.2. Catalyst
  • 2.3. Related Reports

3. Industry Overview

  • 3.1. Types of Biopsies
    • 3.1.1. Surgical Biopsy
    • 3.1.2. Fine Needle Aspiration
    • 3.1.3. Core Needle Biopsy
    • 3.1.4. Vacuum-Assisted Biopsy
  • 3.2. Biopsy Procedure Trends
    • 3.2.1. EU
  • 3.3. Market Access to Cancer Screening Programs
    • 3.3.1. Regulation
    • 3.3.2. Biopsy Device Adoption Patterns
    • 3.3.3. Reimbursement Trends
  • 3.4. Regulatory Issues/Recalls
  • 3.5. Mergers & Acquisitions/Key Partnerships
    • 3.5.1. Hologic Acquires Suros Surgical Systems
    • 3.5.2. C. R. Bard Acquires SenoRx
    • 3.5.3. Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery
  • 3.6. Economic Impact of Cancer Screening and Treatment
  • 3.7. Additional Indications for Biopsy Devices

4. Unmet Needs

  • 4.1. Overview
  • 4.2. More Efficient Screening Tests for Prostate Cancer
  • 4.3. More Efficient Screening Tests for Breast Cancer
  • 4.4. More Efficient Screening Guidelines for Thyroid Cancer
  • 4.5. Screening Tests That Can Provide Histological Analysis In Situ

5. Market Opportunity Analysis

  • 5.1. Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries
  • 5.2. Bundling Solutions
  • 5.3. Focus Efforts on China's Increasing Adoption of VAB Devices
  • 5.4. Market for Prostate Cancer Screening Coverage in Europe

6. Market Drivers and Barriers

  • 6.1. Market Drivers
    • 6.1.1. Inadequate Screening Tests for Particular Cancers
    • 6.1.2. Demand for Minimally-Invasive Biopsy Techniques
    • 6.1.3. Increased Adherence to Certain Cancer Screening Guidelines
    • 6.1.4. Aging Patient Population
  • 6.2. Market Barriers
    • 6.2.1. Increased Competition from Other Cancer Diagnostic Tests
    • 6.2.2. Breast Biopsy Reimbursement Bundling
    • 6.2.3. Decreased Adherence to Certain Cancer Screening Guidelines
    • 6.2.4. Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Classification Based on System
    • 7.2.1. Vacuum-Assisted Biopsy Devices
    • 7.2.2. Core Needle Biopsy Devices
    • 7.2.3. Fine Needle Aspiration Devices

8. Pipeline Assessment

  • 8.1. Overview
    • 8.1.1. Optical Biopsy
    • 8.1.2. Liquid Biopsy

9. Clinical Trial Analysis

10. Current and Future Players

  • 10.1. Trends in Corporate Strategy
  • 10.2. Company Profiles
    • 10.2.1. Argon Medical Devices
    • 10.2.2. Boston Scientific
    • 10.2.3. Cardinal Health
    • 10.2.4. CareFusion Corporation
    • 10.2.5. Cook Medical
    • 10.2.6. C. R. Bard
    • 10.2.7. Devicor Medical Products
    • 10.2.8. DTR Medical
    • 10.2.9. Gallini Medical Devices
    • 10.2.10. Hologic
    • 10.2.11. INRAD
    • 10.2.12. Intact Medical Corporation
    • 10.2.13. TSK Laboratory

11. Market Outlook

  • 11.1. Company Market Share
    • 11.1.1. Vacuum-Assisted Biopsy Market Share
    • 11.1.2. Core Needle Biopsy/Fine Needle Aspiration Market Share
  • 11.2. By Segment
    • 11.2.1. Fine Needle Aspiration
    • 11.2.2. Core Needle Biopsy
    • 11.2.3. Vacuum-Assisted Biopsy
  • 11.3. By Geography
    • 11.3.1. France
    • 11.3.2. Germany
    • 11.3.3. Italy
    • 11.3.4. Spain
    • 11.3.5. United Kingdom

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Report Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Primary Research
    • 12.3.4. Secondary Research
    • 12.3.5. Forecasting Methodology
  • 12.4. Key Opinion Leaders Included in This Study
  • 12.5. About the Authors
    • 12.5.1. Joseph A. Gregory, Analyst, Surgical Devices
    • 12.5.2. Derek Archila, MBA, Director of Research and Analysis, Medical Devices
  • 12.6. Global Head of Healthcare
    • 12.6.1. Bonnie Bain, Ph.D., Global Head of Healthcare
  • 12.7. About MediPoint
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019
  • Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019
  • Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019
  • Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019
  • Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019
  • Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019
  • Table 7: Age Demographics, Age >65 Years, Global, 2013
  • Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011
  • Table 9: Stereotactic Breast Biopsy Physician Billing, 2011
  • Table 10: Company Profile - Argon Medical Devices
  • Table 11: Product Portfolio - Argon Medical Devices
  • Table 12: Argon Medical Devices, SWOT Analysis, 2013
  • Table 13: Company Profile - Boston Scientific
  • Table 14: Product Portfolio - Boston Scientific
  • Table 15: Boston Scientific SWOT Analysis, 2013
  • Table 16: Company Profile - Cardinal Health
  • Table 17: Product Portfolio - Cardinal Health
  • Table 18: Cardinal Health SWOT Analysis, 2013
  • Table 19: Company Profile - CareFusion Corporation
  • Table 20: Product Portfolio - CareFusion
  • Table 21: CareFusion, SWOT Analysis, 2013
  • Table 22: Company Profile - Cook Medical
  • Table 23: Product Portfolio - Cook Medical
  • Table 24: Cook Medical, SWOT Analysis, 2013
  • Table 25: Company Profile - C. R. Bard
  • Table 26: Product Portfolio - C. R. Bard
  • Table 27: C.R. Bard, SWOT Analysis, 2013
  • Table 28: Company Profile - Devicor Medical Products
  • Table 29: Product Portfolio - Devicor Medical Products
  • Table 30: Devicor Medical Products SWOT Analysis, 2013
  • Table 31: Company Profile - DTR Medical
  • Table 32: Product Portfolio - DTR Medical
  • Table 33: DTR Medical SWOT Analysis, 2013
  • Table 34: Company Profile - Gallini Medical Devices
  • Table 35: Product Portfolio - Gallini Medical Devices
  • Table 36: Gallini Medical Devices SWOT Analysis, 2013
  • Table 37: Company Profile - Hologic
  • Table 38: Product Portfolio - Hologic
  • Table 39: Hologic SWOT Analysis, 2013
  • Table 40: Company Profile - INRAD
  • Table 41: Product Portfolio - INRAD
  • Table 42: INRAD SWOT Analysis, 2013
  • Table 43: Company Profile - Intact Medical Corporation
  • Table 44: Product Portfolio - Intact Medical Corporation
  • Table 45: Intact Medical Corporation SWOT Analysis, 2013
  • Table 46: Company Profile - TSK Laboratory
  • Table 47: Product Portfolio - TSK Laboratory
  • Table 48: TSK Laboratory SWOT Analysis, 2013
  • Table 49: VAB, Global Market Share, 2013
  • Table 50: CNB/FNA, Global Market Share, 2013
  • Table 51: EU FNA Device Sales ($m) Forecast, 2010-2019
  • Table 52: EU CNB Device Sales ($m) Forecast, 2010-2019
  • Table 53: EU VAB Device Sales ($m) Forecast, 2010-2019
  • Table 54: France Biopsy Devices Sales ($m) Forecast, 2010-2019
  • Table 55: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019
  • Table 56: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019
  • Table 57: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019
  • Table 58: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019

List of Figures

  • Figure 1: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019
  • Figure 2: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019
  • Figure 3: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019
  • Figure 4: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019
  • Figure 5: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019
  • Figure 6: EnCor Breast Biopsy System
  • Figure 7: EnCor Enspire Breast Biopsy System
  • Figure 8: EnCor Ultra Breast Biopsy System
  • Figure 9: Finesse Ultra Breast Biopsy System
  • Figure 10: Vacora Breast Biopsy System
  • Figure 11: Original Mammotome System
  • Figure 12: Mammotome Elite
  • Figure 13: Mammotome Revolve
  • Figure 14: VAB, Global Market Share, 2013
  • Figure 15: CNB/FNA, Global Market Share, 2013
  • Figure 16: EU FNA Device Sales ($m) Forecast, 2010-2019
  • Figure 17: EU CNB Device Sales ($m) Forecast, 2010-2019
  • Figure 18: EU VAB Device Sales ($m) Forecast, 2010-2019
  • Figure 19: France Biopsy Devices Sales ($) Forecast, 2010-2019
  • Figure 20: Germany Biopsy Devices Sales ($) Forecast, 2010-2019
  • Figure 21: Italy Biopsy Devices Sales ($) Forecast, 2010-2019
  • Figure 22: Spain Biopsy Devices Sales ($) Forecast, 2010-2019
  • Figure 23: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019
Back to Top